CMV-specific T-cells

Unknown Manufacturer

Generate AI report

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Use of Triplex CMV Vaccine in CAR T Cell Therapy
US 2019247500 A1Applicant: HOPE CITYPriority: 2016
US
WO
7 publications
CAR for treatment of HIV infection
US 12496338 B2Applicant: HOPE CITYPriority: 2017
US
WO
4 publications
IMMUNOSUPPRESSANT-RESISTANT T-CELLS FOR ADOPTIVE IMMUNOTHERAPY
- EP 4196572 B1
  Applicant: UNIV BERLIN CHARITEPriority: 2020
  EP
  US
  WO
  3 publications
- EP 3957720 A1
  Applicant: UNIV BERLIN CHARITEPriority: 2020
  CN
  EP
  2 publications
Methods of treating CMV retinitis by T cell therapy
US 10342864 B2Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERPriority: 2015
CN
US
3 publications
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
US 11116834 B2Applicant: HOPE CITYPriority: 2017
US
3 publications
Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
US 2011243841 A1Applicant: IMMUNOMEDICS INCPriority: 2011
US
2 publications
Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
US 11001830 B2Applicant: MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFTPriority: 2015
US
2 publications
DcR3 (Decoy Receptor 3) and GAD65 (Glutamic Acid Decarboxylase 65) double gene co-expression recombinant adenovirus as well as preparation method and application thereof
CN 101875920 BApplicant: UNIV PLA 3RD MILITARY MEDICALPriority: 2009
CN
VSIG4 (V-set and Ig domain containing 4) and IGRP (glucose-6-phosphatase catalytic subunit-related protein) dual-gene coexpression recombinant adenovirus as well as preparation method and application thereof
CN 101818133 BApplicant: UNIV PLA 3RD MILITARY MEDICALPriority: 2009
CN
BITRANSGENIC MURINE MODEL FOR STUDYING MYELOPOIESIS, IMMUNITY AND TUMORIGENESIS
US 2012204274 A1Applicant: YAN CONGPriority: 2012
US

Drugs

CMV-specific T-cells

Patents

IMMUNOSUPPRESSANT-RESISTANT T-CELLS FOR ADOPTIVE IMMUNOTHERAPY